OncoMatch/Clinical Trials/NCT04515836
Olaparib in Patients With HRD Malignant Mesothelioma
Is NCT04515836 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Olaparib for mesothelioma.
Treatment: Olaparib — In this study, researchers will give olaparib (a drug) to mesothelioma patients who have specific changes in their DNA (known as gene mutations). Researchers will give this drug to each patient on the study to find out if it will help the patient's tumor shrink or stop growing.
Check if I qualifyExtracted eligibility criteria
Cancer type
Mesothelioma
Biomarker criteria
Required: BAP1 loss
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: platinum-based chemotherapy (cisplatin, carboplatin)
Cannot have received: parp inhibitor (olaparib)
Lab requirements
Blood counts
normal bone marrow function measured within 28 days prior to receiving study treatment
Kidney function
normal organ function measured within 28 days prior to receiving study treatment
Liver function
normal organ function measured within 28 days prior to receiving study treatment
Patients must have normal organ and bone marrow function measured within 28 days prior to receiving study treatment. Normal bone marrow and organ function will be assessed using specific lab tests/ criteria set by the study's lead physician.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Chicago Medical Center · Chicago, Illinois
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify